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Background: Drug resistance in Mycobacterium tuberculosis is associated with chromosomal
mutations in selected genes. These mutations can be screened for an early warning system
for drug-resistant tuberculosis. The prevalence of individual mutations differs geographi-
cally, which must be considered in developing globally applicable screening tests.
Methods: In order to analyse the geographical distribution and frequency of mutations con-
ferring resistance to rifampicin, isoniazid and fluoroquinolones, the researchers investi-
gated the presence of mutations in the rpoB gene, the katG gene, the mabA-inhA
promoter region and the gyrA gene in clinical isolates of multidrug-resistant tuberculosis
(MDR-TB) from Belarus, China, Iran/Iraq, Honduras, Romania and Uganda. For each study
site, the researchers described the distribution of specific mutations in 20 clinical MDR-iso-
lates.
Results: The distribution of resistance-related mutations varied significantly between the
study sites. Settings with a high incidence of MDR-TB, such as Belarus, showed a narrower
spectrum of mutations related to rifampicin and isoniazid resistance and also a higher
prevalence of fluoroquinolone resistance than study sites with a lower MDR-TB prevalence.
Conclusion: This study confirms that there are significant geographical differences in the
distribution of resistance-related mutations and suggests that an increased understanding
of such differences in the specific distribution of resistance conferring mutations is crucial
for development of new, generally applicable, molecular tools for rapid diagnosis of drug--African Society for Mycobacteriology. All rights reserved.
Institute for Communicable Disease Control, SE 171-82 Solna, Sweden. Tel.: +46 8 457 24 31;
. Hoffner).
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settings was seen suggests that much of the problems in these settings can be a result of an
ongoing transmission of certain MDR-TB strains.
 2012 Asian-African Society for Mycobacteriology. All rights reserved.Introduction with 20 isolates, except Iraq and Iran that contributed tenGlobally, it is estimated that multidrug-resistant tuberculosis
(MDR-TB) affects around 650,000 patients [1]. This form of the
disease is resistant to at least isoniazid (INH) and rifampicin
(RIF), the main first-line drugs used for tuberculosis (TB) treat-
ment [1]. Mismanagement of MDR-TB treatment has caused
the development of extensively drug-resistant TB (XDR-TB),
defined as MDR-TB also resistant to any of the fluoroquino-
lones and at least one of the injectable second-line drugs
[2]. In some countries, MDR/XDR-TB constitutes a major
threat to public health and jeopardizes TB control. Alarming
data was recently reported from Belarus where a prevalence
of MDR-TB among infectious cases in Minsk was shown to
be 49%. Among newly detected patients with infectious
(smear positive) pulmonary disease, 35% had MDR-TB and
no less than 76% was found in previously treated cases [3].
This is the highest level ever seen of MDR-TB and constitutes
a severe challenge for TB control efforts.
Rapid and accurate detection of MDR/XDR-TB is a priority.
Timely laboratory diagnosis allows for optimizing therapy
and limiting transmission. This is best achieved using molec-
ular screening for resistance-related mutations. Such molec-
ular-based methods have been developed for the timely
detection of resistance in Mycobacterium tuberculosis based
on the knowledge of genetic mechanisms causing drug resis-
tance. Several genetic biomarkers have been identified and
shown to be related to phenotypic drug resistance. Among
these, an 81 bp region in rpoB gene contains more than 95%
of the mutations seen in clinical isolates resistant to RIF
[4,5]. The katG gene [6,7], the promoter region of the mabA-
inhA operon [8], have been shown to be associated with
INH-resistance.
To make sure that the tests are globally applicable,
researchers need to know not only which genes and muta-
tions are responsible for resistance, but also their global
distribution.
The purpose of this study was to explore the distribution
of resistance-related mutations in MDR-TB isolates from se-
ven countries on four continents.
Materials and methods
Mycobacterium tuberculosis isolates and study sites
The molecular characterization was conducted at the Swed-
ish Institute for Communicable Disease Control (SMI), with
a convenience sample of 120 clinical MDR M. tuberculosis
samples collected over somewhat different time periods:
Belarus (April–August 2009), China (June 2008–September
2009), Honduras (1994–1995/2004–2009), Iraq (June 2008–June
2009), Iran (May 2008–May 2009), Romania (2007–2008) and
Uganda (February 2008–July 2009). Each site contributedstrains each.
Both the in vitro drug susceptibility testing (DST) and the
DNA extraction were performed on site in each collaborating
center with their respective standard technique. The DST
methods used were the absolute concentration method on
Lo¨wenstein-Jensen (LJ) medium [9] (Belarus, Romania) and
the proportion method on LJ medium [10] (Iran, China, Hon-
duras, Uganda). Bactec MGIT 960 (Becton Dickinson, Sparks,
Maryland, USA) [11] was used for ofloxacin (OFX) testing of
the Honduran isolates at SMI. The critical concentrations
were 0.2/0.1 mg/L for INH, 40.0/1.0 mg/L for RIF and 2.0/
2.0 mg/L for OFX for LJ andMGITrespectively. In Belarus a crit-
ical concentration of 1 mg/L was used for INH.
PCR amplification and sequencing
DNA isolation was performed as previously described [12,13].
The DNA extracts were amplified and sequenced to identify
mutations in the rifampicin resistance-determining region
(RRDR) of the rpoB gene [4,5]; the katG gene [6,7], themabA-inhA
promoter region [8] and the quinolone resistance-determining
region (QRDR) in the gyrA gene [14,15]. Polymerase chain reac-
tion (PCR) mixtures (50 ll) contained 5 ll 10· PCR buffer,
0.2 mM dNTP, 1 U Ampli Taq Gold polymerase (Applied Bio-
systems, USA), 0.2 mM of each appropriate pair of primers
(Invitrogen, Life Technologies, UK) and 2 ll of DNA extracts.
PCR thermal cycling conditions and primers sequences, as
well as MgCl2 concentrations used are presented in Table 1.
The PCR products were verified by gel electrophoresis and
purified using the GFXTM PCR DNA and gel band purification kit
(GE Health Care, Amersham, Little Chalfont, UK).
The purified PCR products were sequenced using the ABI
PRISM BigDye Terminator v3.1 cycle sequencing kit and ana-
lyzed in an ABI 3130xl genetic analyzer (Applied Biosystems,
CA, USA), following the manufacturer’s recommendations.
The DNA sequences were aligned using the CLUSTALW algo-
rithm [16]. All mutations found were compared with the
TBDReaMDB database [17].
Results
Of the total of 120 DNA extracts from MDR-TB strains contrib-
uted by the different centers, 117 (97.5%) could be genetically
characterized.
Rifampicin
A clear majority of 94% (110/117) of the MDR-TB isolates had
mutations in the RRDR of rpoB. In three of the study sites all
20 isolates had rpoB mutations, while only 85% of the isolates
from Romania and Iran/Iraq showed such mutations. Of all
the 110 mutations detected, 89% showed single, and 5%
Table 1 – Primers and conditions used to amplify and sequence the MDR M. tuberculosis isolates.
Gene Fragment
size (bp)
Primers (5 0 ! 3 0) PCRa Cycle sequencing PCRb
rpoB 382 OPRIF-F
CGG TCG GCG AGC TGA TCC
OPRIF-R
TTG ACC CGC GCG TAC ACC
95 C/45 s,
53 C /45 s,
72 C /45 s
94 C /10 s (Initial denaturation),
94 C/10 s,
53 C/10 s,
60 C/4 min
katG 704 F 768
CAT GAA CGA CGT CGA AAC AG
R1458
GCT ACC ACG GAA CGA CGA C
95 C/30 s,
52 C /30 s,
72 C /1 min
96 C /1 min(Initial denaturation),
96 C/10 s,
50 C/5 s,
60 C/4 min
mabA-inhA
Promoter
region
1973 SEP(F1)
CGG AAA TCG CAG CCA CGT TA
SEP(R1)
CCA CGC AGA TGT CGC AAA GA
inhA seq rev 925
CCG GAC CCT GGT GCT CTT CT
95 C/45 s,
40 C /30 s,
72 C /3 min
96 C /30 s (Initial denaturation),
94 C/10 s,
50 C/10 s,
60 C/4 min
gyrA 602 gyrA F180
CCT CGG TTC GTC TGT TGC GTC AAG T
gyrA R422
ATC TCC ATC GCC AAC GGG GTC A
95 C/45 s,
56 C /45 s,
72 C /1 min
96 C /30 s (Initial denaturation),
94 C/10 s,
50 C/10 s,
60 C/4 min
a All PCR reactions had an initial denaturation at 95 C/10 min, 30 cycles, final elongation at 72 C/7 min.
b Cycle sequencing PCR reactions used the same primers, except for mabA-inhA (primer inhA seq rec 925) and had 30 cycles.
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dons were 531 and 526, found in 61 (52%) and 38 (32%) strains,
respectively. The distribution of mutations related to MDR-TB
differed significantly between the different settings. For
example, the His526Tyr mutation was mainly found in Roma-
nian isolates and the His526Asp mutation mostly in isolates
from Belarus. No deletions or insertions were detected. Table
2 summarizes all the rpoB mutations detected.
Isoniazid
Most of the MDR-TB isolates (82%) had a mutation in katG
and/or the mabA-inhA promoter region conferring INH-resis-
tance. The most common mutation was katG Ser 315Thr
found in 83 strains (71%), including 20 strains also showing
a mabA-inhA (C-15T) mutation.
Also for INH-resistance, a distinct difference was seen in
the prevalence of the mutations between the different study
settings (Table 3). Most of the strains with mutations both
in the katG gene and the mabA-inhA promoter region were
from Romania and Belarus. The two isolates found with
katG Ser315Thr and mabA-inhA T-8 C genotype were both
from Belarus. Strains without mutations in katG or mabA-
inhA were mainly from Honduras and Iraq. For one Ugan-
dan isolate, a repeated lack of amplification was observed
of the katG locus, which might indicate a deletion of this
gene. A lack of mutations in rpoB, katG and mabA-inhA pro-
moter regions were found in two isolates from Iran and two
from Romania.
Fluoroquinolones
In contrast to the other drugs studied, phenotypic susceptibil-
ity data were missing for fluoroquinolones (FQs). Based on ge-
netic characterization, the level of FQ-resistance differed
significantly between the MDR-TB strains isolated in differentstudy sites. Most frequently, FQ-related mutations were seen
in isolates from Belarus and Romania, with 40% and 35% of
the strains having mutations in the QRDR. In isolates from
Honduras, no such mutations were seen, and in Uganda
and Iran less than 10% of the MDR-isolates carried a QRDR
mutation. Altogether, a total of 30 strains (26%) hadmutations
in the gyrA gene. Of those, 22 had FQ-resistance-related
mutations in the QRDR. The most common mutation was
the substitution Asp94Gly (Table 4).
The single substitution Thr80Ala found in eight Ugandan
isolates is not considered to be related to FQ-resistance, but
rather seen as an epidemiological marker.
Phenotypic DST results for FQ were only available for 56 of
the MDR-TB isolates: from Belarus (20 strains), Honduras (20
strains), Romania (4 strains) and Uganda (12 strains). A full
comparison between genetic and phenotypic detection of
drug resistance was thus not possible.
Eight out of the nine phenotypically FQ-resistant strains
detected in this subset, all from Belarus, had resistance-re-
lated mutations in the QRDR. The mutations Ala90Val and As-
p94Val were the most common (3 isolates each). Among the
47 phenotypically FQ-susceptible strains, 3 had the single
mutation Thr80Ala and 1 had the double mutation Thr80A-
la + Asp94Gly. The remaining 43 susceptible isolates had a
wild type QRDR.
Thirteen of the 61 strains without phenotypic OFX-DST re-
sults had resistance-related mutations in the QRDR. The sub-
stitution Asp94Gly was the more frequent (4/13), followed by
the Ala90Val mutation (3/13). The majority of these were from
Romania (7 isolates) and China (4 isolates).
The overall distribution of mutations found in gyrA is
shown in Table 4. Taking into account the frequency of FQ-
resistance-related mutations only, both Belarus and Romania
have a high level of resistance with 40% and 35% of MDR-TB
isolates also being resistant to FQ. In contrast, only a minority
Table 2 – Distribution of rpoB mutations in 117 MDR-TB isolates.
Amino acid
position
Nucleotide
change
Amino acid
change
No. of
isolates
Belarus China Honduras Irana Romania Uganda
513 CAA! AAA Gln! Lys 2 – – 1 – – 1
CAA! CCA Gln! Pro 2 – – – – 2 –
516 GAC! GTC Asp! Val 6 – 2 1 1 1 1
526 CAC! TGC His! Cys 1 – 1 – – – –
CAC! CTC His! Leu 1 – 1 – – – –
CAC! CGC His! Arg 4 – – 1 2 – 1
CAC! TAC His! Tyr 14 – 3 1 – 10 –
CAC! GAC His! Asp 14 8 2 1 – 2 1
531 TCG! CAG Ser! Gln 1 – – – 1 – –
TCG! TTG Ser! Leu 54 9 7 11 11 2 14
TCG! TTC Ser! Phe 3 – – 3 – – –
TCG! TGG Ser! Trp 2 – – – – – 2
509 and 526 AGC! ACC and
CAC! CTC
Ser! Thr and
His! Leu
1 1 – – – – –
512 and 526 AGC! AAC and
CAC! TAC
Ser! Asn and
His! Tyr
1 – – 1 – – –
520 and 522 CCG! TCG and
TCG! TTG
Pro! Ser and
Ser! Leu
1 – – – 1 – –
526 and 531 CAC! CTC and
TCG! TGG
His! Leu and
Ser! Trp
1 – – – 1 – –
526 and 533 CAC! AAC and
CTG! GTG
His! Asn and
Leu! Val
2 2 – – – – –
WT 7 – 1 – 3 3 –
Total 117 20 17 20 20 20 20
a Includes isolates from Iraqi Kurdistan. WT = wild type.
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 1 ( 2 0 1 2 ) 1 2 4 –1 3 0 127(10–20%) of the isolates from Iran/Iraq and China were resis-
tant, whereas in the isolates from Honduras no mutations
were seen in the QRDR.
Overall mutation profile
This study also analyzed whether the overall mutation profile
for the 4 loci studied related to the geographic origin of the
isolates. At least two mutation profiles (same mutations in
all the target genes) were shared by more than three isolates
from Belarus and Romania. In contrast, the profiles observed
in Honduras, Iran and Uganda were more diverse.
Phylogenetic groups
Mutations in the studied genes were also used for classifica-
tion of M. tuberculosis in phylogenetic groups. Based on katG
463 and gyrA 95 polymorphisms, the MDR-TB isolates were
classified into principal genetic groups (PGGs) [18]. One Ugan-
dan isolate could not be categorized, owing to a lack of ampli-
fication of katG locus. Most isolates belonging to PGG1 (n = 36)
were from China and Iran, reflecting the high prevalence of
ancient M. tuberculosis lineages in these countries. Strains
from Uganda, Honduras and Belarus belonged to the PGG2
(n = 62). The isolates within PGG3 (n = 12) were mainly from
Honduras and Romania.Discussion
As far as this study is concerned, this is the first report of
mutations related to drug resistance in MDR-TB isolates from
Honduras and Romania. The overall results are well in line
with earlier reports from other settings on mutations related
to RIF, INH and FQ-resistance [19–24]. The mutations earlier
reported to be the most common were also most frequently
seen in this study. In addition, two ‘‘new’’ mutations were ob-
served in katG, Arg385Pro and Ser 446Arg, which have not
been reported in the TBDReaMDB database [17].
The most important finding of this study was that the fre-
quency and distribution of mutations detected varied so
much between the different study settings. Belarus, having
the highest prevalence of MDR-TB of all the study sites, had
the narrowest spectrum of RIF and INH-resistance-related
mutations, while isolates from Honduras, Iran/Iraq and Ugan-
da, where MDR-TB is much less frequent, generally had a
more heterogeneous distribution of mutations. A narrow dis-
tribution might indicate an ongoing transmission of MDR.
The fact that Belarus used a higher concentration of INH
(1 mg/L) in their DST might have selected for more highly
resistant isolates. Mutations in katG 315 were seen in all the
Belarusian isolates, a finding that has been previously re-
ported [25]. Consequently, it could be questioned if the lower
level of INH-resistance caused by amutation in themabA-inhA
Table 3 – Distribution of katG and mabA-inhA promoter region mutations in 117 MDR-TB isolates.
Amino acid
position
Nucleotide
change
Amino acid
change
No. of
isolates
Belarus China Honduras Irana Romania Uganda
300 TGG! GGG Trp! Gly 1 – – – 1 – –
315 AGC! ACC Ser! Thr 61 10 10 12 8 6 15
AGC! AAC Ser! Asn 2 – 1 – – 1 –
AGC! ATC Ser! Ile 1 – 1 – – – –
AGC! AGA Ser! Arg 1 – – 1 – – –
385 CGG! CCG Arg! Pro 1 – – – 1 – –
446 AGC! CGC Ser! Arg 1 – 1 – – – –
katG 315 and
inhA-8
AGC! ACC and
T! C
Ser! Thr 2 2 – – – – –
katG 315 and
inhA-15
AGC! ACC and
C! T
Ser! Thr 20 8 1 – – 10 1
katG 434 and
inhA-15
CAG! CCG and
C! T
Gln! Pro 1 – – – – – 1
inhA-15 C! T 5 – 2 2 1 – –
katG NA and
inhAWT
1 – – – – – 1
katG and
inhAWT
17 – 1 5 7 2 2
katG WT and
inhA NA
3 – – – 2 1 –
Total 117 20 17 20 20 20 20
a Includes isolates from Iraqi Kurdistan. WT = wild type. NA = not analyzed.
Table 4 – Distribution of gyrA mutations in 117 MDR-TB isolates.
Amino acid
position
Nucleotide
change
Amino acid
change
No. of
isolates
Belarus China Honduras Irana Romania Uganda
80 ACC! GCC Thr! Ala 8 – – – – – 8
90 GCG! GTG Ala! Val 6 3 2 – 1 – –
91 TCG! CCG Ser! Pro 1 1 – – – – –
94 GAC! AAC Asp! Asn 3 1 1 – – 1 –
GAC! CAC Asp! His 2 – – – – 2 –
GAC! GGC Asp! Gly 7 3 1 – – 3 –
GAC! GTC Asp! Val 1 – – – – 1 –
80 and 94 ACC! GCC and
GAC! GGC
Thr! Ala and
Asp! Gly
1 – – – – – 1
91 and 94 TCG! CCG and
GAC! GGC
Ser! Pro and
Asp! Gly
1 – – – 1 – –
WT 87 12 13 20 18 13 11
Total 117 20 17 20 20 20 20
a Includes isolates from Iraqi Kurdistan. WT = wild type.
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tional DST, and thusmet the criteria for inclusion in this study.
In contrast to theMDR-defining drugs, towhich all included
isolates were resistant, the studied isolates were included
regardless of their resistance to FQ, which in most cases was
unknown. Thus the level of FQ-resistance, reflected by thedetection ofmutations in theQRDRof the gyrA genemight give
an estimate on the level of FQ-resistance in MDR-TB isolates
from the different study sites. The frequency found differed
considerably between these, with the highest frequency of
FQ-resistance-relatedmutations seen in Belarus andRomania,
from where 40% and 35% of the strains had detectable gyrA
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isolates from Honduras, Iran/Iraq and Uganda.
This finding reflects the more severe problem with
FQ-resistance, and thus most likely also with XDR-TB, in East
Europe than in the other sites.
An interesting gyrA mutation pattern among the Ugandan
isolates was observed. The mutation Thr80Ala seen in this
study has been previously reported from African clinical iso-
lates [26] and seems to be an allelic variability marker, not
conferring resistance to FQ [27]. However, when this mutation
occurs simultaneously with a well-known FQ-resistance-re-
lated mutation, the isolates are hypersusceptible to FQ [27].
In this study, one Ugandan ofloxacin-susceptible isolate with
the genotype Thr80Ala + Asp94Gly was seen. In a recent sys-
tematic review, it was postulated that the above-mentioned
pattern might be due to a misclassification of the strains or
due to the presence of a mixture of two different strains
[28]. Further studies on clinical isolates harboring this double
mutation might clarify whether or not there are other suscep-
tibility mechanisms involved in the mutation profile, as well
as its geographical distribution and possible implications for
therapy and on transmission.
The distribution of isolates belonging to the different PGGs
may also be used as an indicator of the epidemiological
trends in our study settings. The predominance of PGG1 iso-
lates in China and Iran reflects the high prevalence in these
countries of ancient M. tuberculosis lineages, such as Beijing
[29] and Central Asian (CAS) [30]. In Romania and Belarus,
mainly PGG 2 and 3 isolates were observed combined with a
less diverse mutation profile. This might indicate that mod-
ern M. tuberculosis lineages, like the Latin American Mediter-
ranean (LAM) and T genotypes, are causing the clonal
spread of MDR and pre-XDR isolates. More in-depth, prospec-
tive epidemiological studies in these settings are needed to
understand the role of non-Beijing genotypes in the occur-
rence of M/XDR-TB.
A theoretical comparison of these findings with a commer-
cially available rapid molecular test, the line probe assay (LPA)
also highlights the importance of knowing the prevalence and
distribution of mutations related to resistance before imple-
menting a new test in any specific setting. If the Genotype
MTBDRplus (Hain Lifescience, Nehren, Germany) [31] would
have been used, 97% of the katG/mabA-inhA mutants and
100% of the rpoBmutants would have been correctly detected.
Thus, the overall test sensitivity would have been very good,
but when site-by-site comparisons are done, only 65% and
75% of the INH-resistant isolates from Iran and Honduras,
respectively, would have been identified as resistant. Simi-
larly, the Genotype MTBDRsl (Hain Lifescience, Nehren,
Germany) [32] would have been able to detect the fluoroquin-
olone-resistance-related mutations owing to its high sensitiv-
ity for the detection of fluoroquinolone resistance, as it has
been reported recently [33].Conclusion
Knowledge of the prevalence of geographic-specific muta-
tions can allow the development of in-house, PCR-based
methods for targeting mutations relevant in a specificsetting. Since there are clear geographical differences in
the presence and proportion of resistance-related muta-
tions, it is crucial to include enough drug-resistant clinical
isolates from various parts of the world when new diagnos-
tic tools aimed at global implementation are developed and
evaluated.
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